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Key Points
• Prophylactic ECP protects
against GVHD in a murine
BMT model.
• ECP provides apoptotic
signals that promote
tolerance through dendritic
cells and Tregs.
Acute graft-versus-host disease (GVHD) is induced by alloreactivity of donor T cells toward
host antigens presented on antigen-presenting cells (APCs). Apoptotic cells are capable of
inducing tolerance by altering APCmaturation. Apoptosis can be induced by extracorporeal
photopheresis (ECP). We demonstrate that the use of ECP as a prophylaxis prior to
conditioning significantly improves survival (P < .0001) after bone marrow transplantation
(BMT) by inhibiting the initiation phase of acute GVHD in a murine BMT model. ECP-treated
autologous splenocytes resulted in immune tolerance in the host, including reduced dendritic
cell activationwith decreased nuclear factor-kB engagement, increased regulatory T-cell
(Treg) numbers with enhanced expression of cytolytic T lymphocyte-associated antigen 4,
potentiating their suppressive function. The protective effect required host production of
interleukin-10 and host Tregs. Conventional T cells that entered this tolerant environment experienced reduced proliferation, as well as
a reductionof tissuehoming andexpressionof activationmarkers. The induction of this tolerant state byECPwasobviatedbycotreatment
with lipopolysaccharide, suggesting that the inflammatory state of the recipient prior to treatment would play a role in potential clinical
translation.TheuseofprophylacticECPmayprovideanalternativeandsafemethod for immunosuppression in thebonemarrowtransplant
setting. (Blood. 2014;124(11):1832-1842)
Introduction
Graft-versus-host disease (GVHD) remains amajor cause ofmorbidity
and mortality after allogeneic bone marrow transplantation (BMT).
GVHD occurs when donor T cells recognize and respond to
alloantigens on antigen-presenting cells (APCs).1,2 The pathophysi-
ology of acute GVHDhas been described as a 3-step phenomenon: (1)
activation of host APCs; (2) the effector phase, characterized by donor
T-cell activation, proliferation, and differentiation; and (3) target tissue
destruction.3 All three steps continue to interact as GVHD progresses.
Strategies to prevent GVHD focus primarily on the effector phase
by inhibiting donor T-cell activation and proliferation. The most
common approach is to administer immunosuppressive drugs that
act in a nonspeciﬁc fashion without inducing true tolerance.
Although effective, these drugs result in signiﬁcant toxicity and risk
for opportunistic infections.4,5 An alternative approach is to engineer
the graft including T-cell depletion or administration of various
subsets of T cells, such as regulatory T cells (Tregs).6-8 Despite the
knowledge of the impact of host APCs on GVHD induction, only
a few preclinical studies have focused on targeting APCs to prevent
GVHD induction.9-12
Professional APCs internalize antigens, display peptides on their
surface, and express costimulatory molecules that guide T-cell
activation. Dendritic cells (DCs), the most potent APC population,
play important roles in induction of immunity and in themaintenance
of tolerance.13 Whether DCs act in an immunogenic vs a tolerogenic
fashion depends on the maturation state and context in which the
antigen is acquired.14 Although immature DCs efﬁciently take-up
antigens but poorly activate T cells, mature DCs shut down antigen
acquisition and upregulate costimulatory molecules to effectively
prime T cells.15 During steady state, immature DCs continuously
encounter apoptotic cells fromnormal tissue turnover. Phagocytosis of
apoptotic cells inhibits the upregulation of costimulatory molecules,
converting immature DCs into tolerogenic DCs (TOL-DCs).16,17
Consequently, T-cell activation in the absence of costimulatory
molecules results in T-cell anergy and induction of Tregs.18,19
Apoptosis can be induced by extracorporeal photopheresis
(ECP), a therapy based on exposure of cells to photoactivatable
8-methoxypsoralen (8MOP) and ultraviolet light A (UVA) irradi-
ation.20 ECP is successfully used to treat established acute and
chronic GVHD especially in patients unresponsive to conventional
immunosuppressive drugs and has been proven successful in
prevention of solid organ rejection.21-23
We hypothesized that administration of apoptotic cells prior to
transplantation would induce unresponsiveness in the majority of
immatureDCs, consequently limit donorT-cell activation, and hence
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reduce GVHD induction. Our data show that the novel use of ECP as
a prophylactic therapy during conditioning prevents GVHD by
inducing tolerance and immunosuppression from immature DCs in
response to proapoptotic signals. These signals increase host Tregs
that also upregulate cytolytic T lymphocyte-associated antigen 4
(CTLA4). Alloreactive T-cell proliferation is impaired andmortality
due to GVHD is signiﬁcantly reduced. Graft-versus-tumor (GVT)
effects are maintained.
Materials and methods
Mice
C57BL/6 (H2kb), BALB/c (H2kd), FVB (H2kq), C57BL/6 IL102/2
(B6.129P2-Il10tm1Cgn/J; H2b), BALB/c IL102/2 (C.129P2(B6)-Il10tm1Cgn/
J; H2d), and AKR/J (H2k) mice were purchased from The Jackson Laboratory.
Luciferase-expressing (luc1) C57BL/6-L2G85 (H2kb) mice were created
as previously described.24,25 C57BL/6-Foxp3DTR mice were a kind gift
from Dr A. Rudensky (Howard Hughes Medical Institute, Memorial Sloan-
Kettering Cancer Center, NY) and BALB.K (H2k) from Dr J. A. Shizuru
(Stanford University, Stanford, CA). Mice were 8 to 12 weeks old, cared for
according to theGuidelines forLaboratoryAnimals and studieswere approved
by Stanford University Administrative Panel on Laboratory Animal Care.
BM transplantation
Micewere conditionedwith total body irradiation (BALB/c: 800 cGy,BALB.K:
700 cGy, C57BL/6: 1000 cGy, split dose). BALB/c mice received an IV
infusion of 53 106 T-cell–depletedBM (TCD-BM) plus 7.53 105 positively
selectedCD41/CD81 conventional T cells (Tcons) from allogeneic C57BL/6
or syngeneic BALB/c mice. In some experiments, conditioned mice were
injected with luc1 C57BL/6-L2G85 Tcons to allow for bioluminescent
imaging (BLI) imaging. In some experiments, BALB/cmice received 13 105
ﬂuorescence-activated cell sorter (FACS)–puriﬁed Tregs (CD41CD25high)
from ECP-treated or nontreated BALB/c 24 hours prior to BMT.
BALB.Kmice received 53 103 puriﬁed hematopoietic stem cells (HSCs:
c-Kit1, Thy1.1lo-int, Sca-11, CD3e2, CD42, CD52, CD8a2, B2202, Gr12,
Mac12, TER-1192) plus 105 Tcons from allogeneic AKR/J mice.
C57BL/6 andC57BL/6-Foxp3DTRmice received 53106TCD-BMplus
1.5 3 106 Tcons from FVB donors. Treg depletion in C57B6-Foxp3DTR
mice was performed by intraperitoneal (IP) injection of 50 mg/g diphtheria
toxin (DT) at day21 and22 prior to BMT.
Mice were housed in autoclaved cages with antibiotic water
(sulfamethoxazole and trimethoprim; Hi-Tech Pharmacal) for a minimum
of 30 days.
ECP treatment
Splenocytes were incubated for 30 minutes with 0.2 mg/mL 8MOP
(UVADEX; Therakos) and exposed to 2 J/cm2 UVA light (UVAR Light
Set; Therakos). After 2 washes, 107 cells were injected IV. For some
experiments, whole splenocytes were incubated with 8MOP but no UV
irradiation. If not indicated otherwise, IV injection of apoptotic cells was
performed 48 hours prior to BMT.
Cell isolation and flow cytometry reagents
Positive selection or depletion for CD41 and CD81 T cells was performed
using anti-CD4 monoclonal antibody (mAb) (clone L3T4) and anti-CD8
mAb (Ly-2) and magnet column separation techniques (Miltenyi Biotec).
Cells were stained and analyzed or sorted using the following reagents: CD4
(GK1.5 or RM4-5), CD8a (53-6.7), CD25 (PC61.5), H-2Kb (AF6-88.5),
Foxp3 (FJK-16s), CD80 (16-10A1), CD86 (GL1), CD40 (HM40-3),MHCII-
IAd (39-10-8), CD69 (H1-2F3), CD44 (IM7), P-Selectin (K02.12), a4b7
(DATK32), CD11c (HL3), CTLA4 (UC10-4B9), NF-kB (pS529), Annex-
inV, Sca-11 (D7), CD3e (17A2), CD5 (53-7.3), B220 (RA3-6B2),Gr1 (RB6-
8C5), Mac1 (M1/70) and TER-119 (TER-199), live/dead ﬁxable Aqua (BD
Biolegend, Invitrogen, or eBiosciences).
Phospho-flow
Cells were stimulated with 5 mg/mL lipopolysaccharide (LPS; 30 minutes,
37°C), ﬁxed with 1.5% paraformaldehyde (PFA) and cold methanol 100%,
followed by intracellular staining. Samples were analyzed and sorted in
a Stanford shared FACS facility (LSRII, FACSAria; Becton Dickinson).
FlowJo software (TreeStar 8.8) was used for data analysis.
In vitro mixed lymphocyte reaction (MLR) culture
BALB/c splenocytes were cultured with or without ECP-treated BALB/c
splenocytes and used as stimulators. After 48 hours, stimulators were
irradiated (30 cGy) followed by addition of carboxyﬂuorescein diacetate
succinimidyl ester (CFSE)–labeledC57BL/6 Tcon responders (stimulators:
responders ratio: splenocytes 4:1; DCs 1:2). After 96 hours, CFSE
(Vybrant CFSE) dilution was quantiﬁed or cells were pulsed with 1 mCi/
well [3H]-thymidine and incorporation was measured with a Wallac
Betaplate counter (PerkinElmer).
In vivo BLI
BLI was performed with an IVIS spectrum charge-coupled device imaging
system as previously described (Xenogen)26; images were analyzed with
LivingImage 3.0 software (Xenogen).
CFSE labeling and pulsed in vivo BrdU labeling
Tconswere labeledwith a 2.5mMCFSETracer kit (Invitrogen) in phosphate-
buffered saline (5 minutes, 37°C). Reaction was quenched by cold RPMI
1640 with 10% fetal calf serum and washed 3 times to remove excess CFSE.
5-Bromo-29-deoxyuridine (BrdU) was injected IP at a dose of 1 mg/mouse
every second day, starting day12 post-BMT.
Cytokine analysis
Supernatants of in vitro MLR assays (96 hours) or serum of experimental
animals from day 15 were stained with Milliplex Immunoassay according
to the manufacturer’s instruction (Millipore) and analyzed using Cytokine
Bead Array (Luminex 200; Bio-Rad). Intracellular cytokines were assessed
by restimulating with phorbol 12-myristate 13-acetate (40 ng/mL) and
ionomycin (2 mM) in presence of monensin (2 mM; Sigma-Aldrich) for
5 hours. Cells were ﬁxed, permeabilized, and assessed for interferon g (INFg)
and tumor necrosis factor a (TNFa).
Cytotoxicity assay and in vivo tumor model
Bcl1 and A20 target cell lines (ATCC) were labeled with 300 mCi/mL 51Cr
(PerkinElmer) at a dose of 23 104 (2 hours, 37°C, 5% CO2). CD8
1 T cells,
isolated 10 days post-BMT, served as effector cells (E) at effector-to-target
(E:T) ratios of 20:1 and 5:1. Radioactivity released into supernatants was
measured after 4 hours of incubation in a scintillation counter. Negative
controls (spontaneous release) were supernatants from 3H-labeled target cell
culture without effector cells.
In vivo Bcl1 tumor model
BALB/c mice were injected IV with 5 3 103 Bcl1 Luc1 (H2d) tumor cells.
After tumor establishment, deﬁned as BLI signal .2 3 106 photons per
second per tumor, mice were transplanted and followed by BLI imaging.
Statistic analysis
Animal survival was analyzed by the log-rank test. To compare donor T-cell
expansion, cytokine levels, surface marker expressions, and cytotoxicity
assay, a 2-tailed Student t test was used (GraphPad Prism). In some cases,
results were pooled from several experiments displaying the fold change
based on Tcon as reference group.
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Results
Host-type apoptotic cells infused prior to transplantation
prolong survival
To investigatewhether the tolerance-inducingeffectof apoptotic cells can
be exploited to reduce GVHD, BALB/c recipients received 107 ECP-
treated BALB/c splenocytes, accounting for 5% to 10% of the whole
splenic pool. Lower cell numbers (2 3 106) showed similar effects
(data not shown). When apoptotic cells were cleared from recipients
(supplemental Figure 1A, see supplemental Data available at the Blood
Web site) and DCs have captured and processed apoptotic cells after
48 hours recipient mice underwent BMT. ECP-treated mice had im-
proved survival (median survival 59 vs 26 days) with a delayed onset
of GVHD compared with control mice treated with only TCD-BM,
Tcons, and 8MOP (Figure 1A). Administration of ECP-treated cells prior
to BMT at day 22 and 25 resulted in similar survival beneﬁt with-
out further improvement (data not shown). In contrast, administration
of ECP-treated cells following BMT at day 12 or 14 showed no
improvement in survival (Figure 1B). To exclude strain-speciﬁc effects,
we performed additional experiments across minor histocompatibility
barriers (AKR/j→BALB.K). The ECP-treated group similarly showed
a signiﬁcant improvement in survival (median survival 37 vs 8 days) with
surviving mice showing no signs of GVHD (Figure 1C). To exclude
a speciﬁc effect of splenocytes as opposed to peripheral blood cells we
performed anMLR using peripheral blood cells as the apoptotic source.
T-cell proliferation was signiﬁcantly reduced (supplemental Figure 1B).
For comparative purposes, we injected donor-type ECP-treated
cells 2 days prior to BMT that resulted in equivalent improvement in
survival and in vitro suppression (supplemental Figure 2).
Uptake of apoptotic cells during steady state reduces NF-kB
activation and costimulatory molecule expression in host DCs
and diminishes trogocytosis in donor T cells
Because nuclear factor-kB (NF-kB) plays an important role in APC
maturation,27 we assessed NF-kB activation by phospho-ﬂow analysis
and observed a signiﬁcantly lower expression in hostDCs inECP-treated
miceascomparedwithuntreatedmice (Figure2A).Furthermore, both the
expressionof thecostimulatorymoleculesCD80/CD86asacharacteristic
of mature DCs and the frequency of DCs were signiﬁcantly reduced. In
contrast, when mice received LPS injections simultaneously with ECP
treatment, DC maturation was restored with similar CD80/CD86
expression in ECP-treated and nontreated animals (Figure 2B-C,
CD86, data not shown). The expression of CD40, CD80, and major
histocompatibility complex II (MHCII) on host-type DCs remained
signiﬁcantly lower 3 days post-BMT in ECP-treated mice (Figure 2D).
Together, the exposure to apoptotic cells favored TOL-DCs17 with low
NF-kB activation and costimulatory molecule expression.
We next examined trogocytosis, a phenomenon characterized by
inﬂammation-dependent incorporation of cell surface proteins
including MHCII by T cells.28 The MHCII uptake on T cells in
ECP-treated mice was signiﬁcantly reduced compared with T cells
from non-ECP-treated mice after allogeneic and syngeneic BMT
(Figure 2E). Interestingly, allogeneic donor T cells showed a speciﬁc
uptake of host MHCII (IAd) but not donor MHCII (IAb).
Reduced T-cell activation and proliferation rather than
peripheral T-cell deletion is responsible for improved survival
Splenocytes were cultured with or without syngeneic apoptotic cells
and served as stimulators in an MLR. Allogeneic T-cell response to
these stimulators was signiﬁcantly reduced in cultures contain-
ing apoptotic cells (Figure 3A). BALB/c mice treated with ECP
showed signiﬁcantly lower T-cell proliferation as assessed by
BLI 4 days after transplantation with C57Bl6 luc1 T cells
compared with untreated mice (Figure 3B). ECP-treated mice
had less weight loss associated with GVHD and a signiﬁcantly
Figure 1. Exposure to host-type apoptotic cells 48 hours prior, but not after
BMT improves survival in GVHD models. (A) ECP treatment 48 hours prior to
BMT in C57BL/6→BALB/c mice improves survival. BALB/c mice injected with
C57BL/6 TCD-BM plus Tcon only (s, n 5 29) or with prior injection of ECP-treated
BALB/c cells (4, n 5 32) or with prior injection of 8MOP but no UV light-treated
BALB/c cells (n, n 5 9). s vs 4, P , .0001 (median survival, 26 vs 59 days). (B)
ECP treatment 2 or 4 days after BMT does not improve survival. BALB/c with TCD-
BM plus Tcon only (d, n 5 10) or followed by ECP treatment with C57BL/6 cells at
day 12 (,, n 5 10) or day 14 (N, n 5 10). (C) ECP treatment 48 hours prior to BMT
across minor histocompatibility barriers in AKR/J→BALB.K improves outcome.
BALB.K injected with purified AKR/J HSC and Tcon alone (s, n 5 10) or with prior
injection of ECP-treated BALB.K cells (4, n 5 10). s vs 4, P 5 .0002 (median
survival, 8 vs 37 days). Significance was assessed using the log-rank test.
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prolonged overall survival. Interestingly, the BLI proliferation
signals in ECP and untreated mice became the same at day 17
after BMT during the effector phase (Figure 3B). We conﬁrmed
the BLI results using CFSE-labeled donor Tcons. We found
signiﬁcantly lower T-cell proliferation in ECP-treated mice
especially among CD41 T cells (Figure 3C). The diminished
proliferation could be due to decreased survival or reduced
activation of donor Tcon cells. Because ECP-treated and
untreated mice had the same level of apoptosis in donor T cells
as assessed by equivalent Annexin V staining (data not shown), it
is probable that decreased proliferation is the result of reduced
activation rather than peripheral deletion. We further observed
lower expression of activation markers CD69 and CD44, skin-
homing marker p-selectin and gut-homing marker a4b7 in
spleen, peripheral lymph nodes (pLNs), and mesenteric lymph
nodes (mLNs) in ECP-treated animals (Figure 4). Reduced
activation and slower trafﬁcking of allogeneic T cells to target
organs during the GVHD initiation phase contributed to the
delayed onset of GVHD.
Uptake of apoptotic cells reduces proinflammatory
cytokine secretion
To determinewhether ECP treatment had an impact on proinﬂammatory
cytokine proﬁles, we evaluated supernatants from MLR cultures of
T cells coincubated with or without ECP-treated cells and found that
coincubation with apoptotic cells resulted in a highly signiﬁcant reduction
of INFg, TNFa, interleukin-6 (IL-6), IL-1b, and IL-2 (Figure 5A).Next,
we compared cytokine proﬁles in serum of transplanted mice 5 days post-
BMT and found a signiﬁcant reduction in the levels of INFg and IL-2 in
the ECP group with a similar trend in TNFa, IL-6, and IL-1b (Figure 5B).
Intracellular INFg production was reduced in CD4 T cells and DCs
indicating the impact of ECP not only on T cells but also on APCs
(Figure5C)whereasTNFa reductionwasonlyobserved inTcells inLNs
during this early time point after BMT (supplemental Figure 3).
Host IL-10 is required for effective ECP treatment
IL-10 has been shown to play a key role in conventional ECP
treatment but the role of IL-10 in preemptive ECP treatment is
Figure 2. Uptake of apoptotic cells reduces NF-kB
activation and costimulatory molecule expression
in host DCs and diminishes MHCII uptake in donor
T cells. (A) NF-kB activation in LPS-challenged BM-
DCs is reduced in ECP-treated mice. Non-ECP-treated
(n) or ECP-treated mice (:) were challenged with LPS
(10 mg/mouse IV) 48 hours after ECP treatment and
NF-kB activation was measured by phospho-flow
staining. BM cells from unchallenged nontreated mice
served as baseline control (d). MFI, Non-ECP-treated
(n) vs ECP-treated (:), P 5 .04. (B) CD80 expression
of DCs is reduced after ECP treatment but restored in
the presence of danger signals during ECP treatment.
Left, DCs in non-ECP-treated (n) or ECP-treated (:)
mice were activated with LPS (10 mg/mouse IV) 48 hours
after ECP treatment and harvested 18 hours after ac-
tivation. MFI of CD80: (n) vs (:) in BM, P , .0001, or
pLN: P 5 .0006. Right, Non-ECP-treated (n) or ECP-
treated (:) mice received additional LPS (10 mg/mouse
IV) at time of ECP treatment 48 hours prior to harvest.
CD80 expression is restored in BM and pLNs. Un-
challenged BM cells from untreated mice served as
baseline control in both experiments (d). (C) DC fre-
quency is reduced after ECP treatment but restored in
the presence of additional danger signals during time
of ECP treatment. Proportional contributions to cellular
content of BM-DCs and pLN DCs from mice in panel B
are shown. (D) Expression of costimulatory molecules
in host-type DCs (H2d) is reduced at day 13 after BMT
in ECP-treated mice. Histograms with MFI of CD40,
CD80, and MHCII on host-type DCs (H2d) from repre-
sentative animals are shown. (E) Trogocytosis is lower
in ECP-treated mice. CD41 T cells were isolated from
pLN at day 15 post-BMT from untreated mice (WT),
syngeneic BMT (BALB/c CD45.1→BALB/c, CD45.2;
Syn) and allogeneic BMT (C57BL/6, H2b→BALB/c, H2d)
with Tcon alone (Tcon) or plus ECP treatment (ECP)
and analyzed for uptake of host MHCII-IAd (H2d) or
donor MHCII-IAb (H2b). pLN: Tcon vs ECP, P 5 .001.
WT represents MHCII expression on CD41 T cells during
steady state in untreated mice. (A-E) One representa-
tive experiment with at least 4 mice per group of 2
independent experiments is shown. Error bars indicate
mean 6 SEM and significance was assessed by 2-
tailed Student t test. MFI, mean fluorescence intensity;
SEM, standard error of the mean.
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unclear.29,30 Although we could not detect differences in serum
levels of IL-10 in ECP-treated vs non-ECP-treated mice, possibly
due to utilization of IL-10 by Tregs (Figure 5D), the survival
beneﬁt after ECP treatment was completely abrogated when
BALB/c IL-10-KO were used as recipients (Figure 5E). These
results evidence that host IL10 is needed in our model. We
evaluated whether IL-10 production is required by donor cells
utilizing IL10-KO animals as donors. We found that mice that
received IL-10-KO donor T cells showed equivalently accelerated
GVHD and death irrespective of ECP treatment even when
compared with the wild-type (WT) Tcon group (Figure 5E).
Although not necessary, we cannot exclude the possibility that
donor IL10 could contribute to ECP protection.
Host-type Foxp31 Treg are required to improve survival but are
not solely responsible for beneficial outcomes
Tregs are major determinants in the success of conventional ECP
treatment.30,31 In our model of preemptive ECP, we observed
a signiﬁcant increase of host but not donor-type Tregs in ECP-treated
mice as comparedwith untreatedmice 5 days post-BMT (Figure 6A).
It is known that Tregs are relatively radio-resistant32 and we
hypothesized that the increase in host Tregs after BMT reﬂected
a persistence of Tregs that were present before irradiation because
host Tregs from ECP and untreated mice did not proliferate after
BMT, as shown by BrdU incorporation assay (Figure 6B). Indeed,
we found a signiﬁcant increase in Tregs in ECP-treated mice with
signiﬁcantly higher surface expression of CTLA4 as compared with
untreated control mice (Figure 6C-D). Importantly, these Tregs
displayed a higher suppressive capability thanWT Tregs in anMLR
assay (Figure 6E).
To determine the functional impact of host Tregs, we applied
speciﬁc Treg depletion, utilizing a C57BL/6-Foxp3-DTR knock-
in strain as recipients (Figure 6F), where Foxp31 Treg can
speciﬁcally be depleted by DT. We observed a signiﬁcant survival
improvement in the WT-ECP as compared with the WT-Tcon
group in the FVB→C57BL/6 strain combination. In contrast, after
host-Treg depletion in C57BL/6-Foxp3DTR mice, ECP treatment
failed to improve survival as compared with the Tcon group.
Control WT-C57BL/6 recipients also treated with DT showed
accelerated death due to DT toxicity, however, the survival beneﬁt
was maintained in the ECP group. Although induction of Tregs
using the ECP approach was associated with a clear survival
beneﬁt throughout all experiments, we sought to clarify the role of
host Treg speciﬁcally. To do this, we infused host-type Tregs from
WT or ECP-treated mice into WT recipients prior to BMT, ex-
pecting higher Treg numbers would reduce GVHD. However,
additional host Tregs had no effect on donor T-cell proliferation
(Figure 6G).
Figure 3. Apoptotic cells reduce T-cell proliferation
in vitro and in vivo. (A) In vitro, T-cell proliferation is
significantly reduced in MLR cultures of whole spleno-
cytes, cultured with or without apoptotic cells for 48 hours,
irradiated with 30 cGy and followed by coculture with
CFSE-labeled allogeneic T cells for 96 hours at a ratio
2:1. FACS histogram of CFSE dilution profile (left) and
bar graphs displaying the proportions of unproliferated
T cells (right) are shown. (B) In vivo, Quantification of
T-cell proliferation shows significant reduction in ECP-
treated mice. BLI on day14 (left, upper panel) shows a
significant reduction in T-cell proliferation among ECP-
treated mice, no difference in BLI signal is observed at
day 17 between both groups (left, lower panel). Quan-
tification of photons per second per mouse (middle;
P 5 .001) and relative weight loss (right; P 5 .0003) of
transplanted mice at day 14 is shown. (C) Ex vivo,
Proportion of T-cell proliferation in reisolated CFSE-
labeled Tcon at day 14 is shown. CD41 and CD81
T cells show lower proliferation index in ECP-treated
mice. Results were done in triplicates (A) and repre-
sent 3 independent experiments or (B) are a composite
of 2 independent experiments or (C) are representative
for 2 individual experiments with a total of 8 to 11 mice
per group. Error bars indicate mean 6 SEM and sig-
nificance was assessed by 2-tailed Student t test.
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GVT effect is maintained after ECP treatment
Approaches to inhibit GVHDcan sometimes reduce or prevent GVT.33
Toaddress this issue,we evaluated the impact ofECP treatment onGVT
effects. In vitro cytotoxicity assays using A20 and Bcl1 tumor cell lines
as target cells and donor CD81 T cells puriﬁed 10 days after BMT, as
effector cells demonstrated persistence of lysis in both ECP and Tcon
groups (Figure7A); however, thedegreeofkilling in theECPgroupwas
reduced against both target cell lines. To evaluate whether this killing
capacity in the ECP group is sufﬁcient to maintain GVT in vivo, we
established theBcl1 tumor in recipientmiceprior toBMT.All recipients
ofT-cell-repletegrafts showedno recurrenceof the tumor irrespectiveof
ECP treatment, whereasmice transplantedwith TCD-BMalone died of
tumor progression (Figure 7B). Thus, ECP treatment did not impair
antitumor responses by allogeneic Tcons in this tumor model.
Discussion
Our work demonstrates that a single dose of host-type ECP-treated
cells prior to transplantation diminishes GVHD and signiﬁcantly
improves survival in murine BMT models. The beneﬁt of ECP-
treated cells depends upon immunosuppressive signals inherent to
apoptotic cells that inhibit maturation of host DCs. Such active
tolerance induction requires host IL-10 production and host Treg
cells. The effectiveness of host-type ECP-treated cells is important
because obtaining host cells is perhaps more amenable to clinical
translation than using donor-type cells.
We evaluated biological attributes of apoptotic cells to gain
insights into the mechanism(s) underlying the beneﬁcial effect
of infusing host ECP-treated cells prior to transplantation. Apopto-
tic cells ﬂip phosphatidylserine, normally located on the inner
membrane, to the outer bilayer and binding to MerTK receptors
on APCs induces active downregulation of NF-kB.34,35 NF-kB
activation in DCs is critical for the upregulation of proinﬂammatory
cytokines and costimulatory molecules, and its inhibition is a
promising approach to reduce T-cell activation in GVHD.15,36-41 In
our model, the uptake of ECP-induced apoptotic cells signiﬁcantly
reduced NF-kB activation in host DCs. The inhibition of NF-kB
activation blocked the maturation of DCs in terms of upregulation of
MHC and costimulatory molecules at the time of transplantation and
resulted in signiﬁcantly lower proinﬂammatory cytokine production.
Consequently, donor T-cell activation was signiﬁcantly reduced
in these mice, which in turn contributed to the reduced secretion
of proinﬂammatory signals. Additionally, the frequency of recipi-
ent DCs was lower in the ECP-treated group with an increase in
apoptotic signals, thus further reducing potential sites of donor T-cell
priming.
Reducing DC antigen presentation to donor T cells is unlikely
the only mechanism to reduce GVHD in ECP-treated animals.
Shlomchik et al recently demonstrated that selective depletion of
host DCs did not ameliorate GVHD.42 It has been shown that up-
take of apoptotic cells by DCs induces Tregs, which when trig-
gered by speciﬁc antigens, can act back via a “feedback loop” on
immature DCs to further block the upregulation of costimulatory
molecules. Additionally, Tregs are able to directly inhibit T-cell
activation by inhibition of CD28 signaling.17,43,44 Previous studies
have shown that Tregs play an essential role in mediating immune
suppression following ECP. Donor Tregs were important to reverse
established GVHD in a murine model and Tregs were found to
be increased in patients with acute and chronic GVHD when suc-
cessfully treated with ECP.30,45,46 In contrast to these studies, we
observed a signiﬁcant increase of host-type Tregs while leaving
donor Tregs unaffected in ECP-treated mice. More importantly,
these ECP-induced Tregs had signiﬁcantly higher surface expression
of the suppressor molecule CTLA4, potentiating their suppressive
capacity.47
The impact of host Tregs was necessary because their speciﬁc
depletion abrogated the beneﬁcial outcome of infusion of ECP-
treated cells. However, the isolated adoptive transfer of host-type
Tregs 24 hours prior to transplantation with the aim of increasing
Treg numbers failed to reduce T-cell proliferation, indicating these
cells alone are likely not sufﬁcient for protection but require the
interplay with other immune-tolerogenic processes or require
activation for functional activity. This result shows that the beneﬁt
of ECP treatment is not solely based on Tregs and highlights the
importance of the immunologic context of these cells.31
Figure 4. CD41 T cells in ECP-treated mice show reduced expression of homing
and activation markers. Donor CD41 T cells (H2b) were reisolated at day14 post-BMT
and fold change based on Tcon as reference group is shown. Expression of activation
markers CD69 and CD44 in spleen and pLN and gut homing marker a4b7 in mLN are
significantly reduced, with skin homing marker p-selectin in pLN showing a similar trend.
Data are pooled from 2 independent experiments with 7 mice per group. Error bars
indicate mean 6 SEM and significance was assessed by 2-tailed Student t test.
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Figure 5. ECP treatment reduces proinflammatory cytokine secretion in vitro and in vivo and requires host type IL-10 for its beneficial effect. (A) Proinflammatory
cytokine secretion into supernatants of MLR cultures is reduced in cells cocultured with apoptotic cells. Purified DCs were cultured with or without apoptotic cells for 48 hours,
stimulated with LPS (2 mg/mL) and cocultured with freshly isolated allogeneic Tcons. Supernatants were harvested after 96 hours. (B) Proinflammatory cytokines are reduced
in serum of mice treated with ECP, although statistical significance was only reached for INFg and IL-2. Serum was obtained 5 days post-BMT. (C) Intracellular INFg
production is reduced in mice treated with ECP 4 days after transplantation. Single-cell suspension from LN and spleen were restimulated for 5 hours with PMA and Ionomycin
in the presence of Monensin. (D) Serum analysis of IL-10 at day 15 shows marginal increase in ECP-treated group. (E) Host-type IL-10 is required for beneficial effect
of ECP treatment. WT BALB/c recipients received either WT donor C57BL/6 Tcon (WT-Tcon, WT-ECP) or IL10-deficient donor C57BL/6 Tcon (Don IL102/2Tcon; Don
IL102/2ECP) and IL10-deficient BALB/c recipient mice received WT C57BL/6 donor Tcon (Rec IL102/2Tcon; Rec IL102/2ECP). ECP was performed with WT BALB/c
splenocytes. Rec IL102/2ECP group showed no beneficial effect of ECP as compared with WT-Tcon or Rec IL102/2Tcon group. Don IL102/2Tcon and Don IL102/2ECP
showed accelerated death as compared with all other groups. Results were done in triplicates (A) and are representative of 3 individual experiments or (B,D) are representative of
2 individual experiments with 10 mice per group or 4 mice per group (C) or are representative of 2 independent experiments with n 5 5 mice per group (E). Don, donor; Rec,
recipient.
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Figure 6. ECP treatment induces host-type Foxp31 Tregs that substantially contribute to but are not solely responsible for improved outcome. (A) Preemptive ECP
treatment specifically increases host-type Tregs in C57BL/6→BALB/c. FACS gating strategy for Tregs isolated at day14 (left), total percentage of Treg, fold increase of host-
type Treg in spleen and pLNs based on Tcon group, and absolute numbers of host Foxp31 cells per spleen are shown (right). (B) Proliferation capacity of Treg after BMT.
Transplanted mice received BrdU injection (1 mg per mouse per IP) every second day followed by pLN harvest at day 17. No proliferation of host-type Treg was observed in
mice transplanted with TCD-BM plus Tcon (left, middle). In mice receiving TCD-BM alone, host and donor-Treg proliferated (right). (C) ECP increases Tregs within 48 hours.
Mice with or without ECP treatment were challenged with LPS (10 mg per mouse per IV) 48 hours after injection of ECP-treated cells and Tregs were analyzed in pLNs. Mice
treated with ECP had significantly higher proportions of CD41/Foxp31 cells, compared with WT mice challenged with LPS only. Unchallenged mice served as a baseline. (D)
CD41 T cells from mice in panel C were evaluated for surface CTLA4 expression. ECP-treated mice had significantly higher levels of CTLA4 expression within the CD41
population (left) and CD41/Foxp31 subpopulation, compared with untreated mice challenged with LPS only. (E) Treg from ECP-treated mice more actively suppressed
T-cell proliferation than WT Tregs. [3H]-Thymidine incorporation of WT C57BL/6 responder Tcons (R) to Balb/c stimulators (S) in the presence of WT Tregs or ECP Tregs at
different Treg to responder ratios is shown, P 5 .035. (F) Specific depletion of host Tregs prior to BMT in FVB→Foxp3DTR-C57BL/6. WT-C57BL/6 recipients received FVB
Tcon (Tcon,:; ECP, n), as control for DT toxicity 1 group received 50 mg/kg DT at day 22 and 21 (WT Tcon1DT, ♦; WT ECP1DT, ▼). To specifically deplete host Tregs,
C57BL/6-Foxp3DTR recipients were injected with 50 mg/kg DT at day 22 and 21 and transplanted with FVB Tcon (Foxp3DTR Tcon, s; Foxp3DTR ECP, N). ECP group
showed significant survival improvement in comparison with Tcon group, n vs:, P 5 .03. Mice injected with DT showed exacerbated GVHD due to DT toxicity in all groups.
Foxp3DTR ECP had no survival benefit in comparison with Foxp3DTR Tcon whereas benefit was maintained in WT ECP 1 DT vs WT Tcon 1 DT. (G) Adoptive transfer of
host-type Tregs into untreated recipients prior to BMT failed to inhibit donor T-cell proliferation. Recipient mice received 105 sort-purified Tregs (CD41CD25high) 24 hours prior
to BMT. Tregs originated either from WT BALB/c (WT Treg) or from mice treated with ECP (ECP Treg). Recipients were transplanted with luc1Tcon and followed by BLI
imaging. Data are representative (A,B,C,F,G) of at least 2 individual experiments with 3 to 10 mice per group, or (D) are a composite of 2 experiments with 10 mice per group
or are done in triplicates with 3 independent mice (E). Error bars indicate mean 6 SEM and significance was assessed by 2-tailed Student t test and log-rank test.
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Previous reports have demonstrated the importance of donor-
derived IL-10 to augment BM engraftment by ECP.29 In our model,
mice transplanted with IL-10–deﬁcient donor cells died rapidly
irrespective of ECP treatment, thus not allowing for an evaluation of
the impact of donor IL-10 on prophylactic ECP treatment. However,
when recipient mice were deﬁcient in IL-10 production the beneﬁcial
effect of ECP was completely abrogated. The effect could neither
be rescued by IL-10 released from apoptotic leukocytes nor by
transplantation of IL-10–producing donor cells 48 hours later,
indicating thenecessityof IL-10 in the recipient at the timeofECP.29,31
The role of trogocytosis has not yet been well evaluated in ECP
and BMT. Under inﬂammatory conditions, T cells incorporate cell
surface proteins including MHCII molecules from DCs and other
APCs that enable them to serve as APC-like cells hence driving local
inﬂammation.48 We observed signiﬁcantly lower MHCII expression
on donor T cells in ECP-treated mice as compared with control
groups, most likely due to the repressed proinﬂammatory milieu in
ECP-treated mice. We hypothesize that the inhibition of trogocytosis
by ECP contributes to reduce local inﬂammation. Further experi-
ments to block trogocytosis are needed, however, approaches that
can be used in vivo in the setting of transplantation are lacking.
Importantly, despite the tolerogenic environment created by
ECP, GVT was not impaired in our model. This is consistent with 2
retrospective clinical studies where ECP was part of the preparative
regimen. Although overall and disease-free survival was signiﬁ-
cantly improved and incidence of severe acute GVHD (grade III-IV)
was lower than expected in these high-risk patients, it did not appear
to increase relapse rates or the risk of opportunistic infections that
have been observed in other attempts to prevent GVHD.10,49,50
Furthermore, T- and B-cell responses to novel and recall antigens
remained intact in patients treated with ECP.51
Wehave shown for theﬁrst time that GVHD is reducedwhenECP
is performed prior to transplant conditioning. ECP treatment early
after transplantation (day 12 or 14) failed to protect mice from
GVHD, a ﬁnding that contrasts previous reports on the protective
function of early posttransplant ECP in mice.29 This discrepancy
could be explained by differences in model systems where posttrans-
plant ECP may be protective with less intense conditioning and
allogenicity because the tolerizing effect can be overcome by
additional danger signals in a dose-dependent manner.29,52-54 In our
model, when we injected LPS simultaneously with ECP-treated cells,
we observed restoration of CD80/86 expression on DCs as an
indicator for DC maturation, and mice treated with ECP shortly after
conditioning showed no survival beneﬁt. These results suggest that
DCsensitivity toECP is highly contextual and themicromilieu during
DC maturation is the key variable for the functional activity of
Figure 7. GVT effect is maintained after ECP
treatment. (A) Specific killing of target (T) tumor cell
lines A20 (left) and Bcl1 (right) by effector CD81 T cells
(E) is shown. CD81 T cells were isolated from ECP-
treated (ECP) or nontreated (Tcon) mice 10 days after
BMT and were added to 51Cr-labeled target cells at an
E:T ratio of 20:1 and 5:1. Specific killing occurred in
both target cells, but with reduced efficiency in ECP-
treated mice. (B) GVT effects in vivo are maintained in
ECP-treated mice in a Bcl1 tumor model. Recipients
were injected with 5 3 103 luc1Bcl1 cells 9 days prior
to BMT. Tumor-bearing recipients were transplanted
with Tcon alone (blue, :), or additionally received
ECP-treated splenocytes from healthy mice (red, ▼)
48 hours prior to BMT. Results are done in triplicates
and are representative of 2 individual experiments (A)
or are compiled from 2 experiments with 10 mice per
group (B).
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DCs to induce tolerance vs immunity. Danger signals, inherent to
conditioning and transplantation, such as uric acid or adenosin
triphosphate, could therefore reduce the efﬁcacy of early posttrans-
plant ECP despite the induction of high amounts of apoptotic
cells.29,53,54
Prophylactic ECP did not completely eliminate the presenta-
tion of host antigens to donor effector cells but signiﬁcantly
delayed the induction of donor T-cell priming. Later onset of acute
GVHD may itself have a beneﬁcial effect, as it permits more
recovery time from the preparative regimen, resulting in better
immune reconstitution and less organ damage.55 Controlling this
delay marks an important strategy that is the underlying rationale
for newer immunosuppressive and nonmyeloblative strategies
such as posttransplant cyclophosphamide.56
It is arguable that more frequent courses of ECP prior to BMT
may enhance the beneﬁt, however, in our murine model additional
ECP treatment at day 25 did not improve outcomes further. The
timingmight relate to the effective generation of newDCs capable of
antigen presentation and the short lifespan ofDCs once they captured
apoptotic cells.13 Increasing apoptotic cell numbers is another
strategy but this may be constrained by the saturation of HMGB1,52
which reverses theDC response by leading to immune induction, and
as noningested apoptotic cells undergo secondary necrosis they
provide additional danger signals.57
In conclusion, we show that prophylactic ECP prior to BMT
signiﬁcantly improved survival in a murine BMT model. Because
ECP treatment is safer than many other immunosuppressive
approaches and widely used, our study supports the evaluation of
prophylactic ECP in reducing transplant complications like GVHD
in future prospective clinical studies.
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